source
- Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting rare blood cancersEli Lilly announced it will acquire Calytrix Bio, a Massachusetts biotech, in a deal valued at up to $1.5 billion. Calytrix focuses on precision therapies for myeloproliferative neoplasms, includi…
- Choosing the Right AI Infrastructure Is Key to Accelerating Future Drug DiscoveriesScientific AI is reshaping drug discovery by allowing developers to predict molecule behavior and design new compounds using models trained on protein structures, genomic data, and experimental res…